Klemm Nancy, Schimmer Roman R, Konrad Nils K, Thelen Flavian, Fullin Jonas, Topçu Ebru, Koch Christian, Treacy Milena, Leventhal Matthew Joseph, Bühler Marco M, Lysenko Veronika, Theocharides Alexandre P A, Kurppa Kari J, Balabanov Stefan, Baubec Tuncay, Krivtsov Andrei V, Miller Peter G, Armstrong Scott A, Ebert Benjamin L, Manz Markus G, Nombela-Arrieta Cesar, Boettcher Steffen
Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Res. 2025 Jun 2;85(11):1978-1996. doi: 10.1158/0008-5472.CAN-24-1136.
Missense mutants of p53, such as the frequent hotspot variant R248Q, exert a dominant-negative effect (DNE) on wild-type (WT) p53 in cancer cells with monoallelic TP53 mutations. However, the precise functional and molecular mechanisms of the DNE have remained elusive due to a lack of appropriate model systems. In this study, we developed a variety of model systems, including CRISPR-edited human isogenic cell lines and transcriptional reporter cell lines, and targeted protein degradation assays that were combined with functional and molecular analyses to functionally characterize the DNE. Formation of heterotetramers between R248Q and WT p53 impaired proper WT p53 functionality by preventing DNA binding and subsequent target gene transactivation. Furthermore, the markedly increased protein half-life of R248Q led to supraphysiologic levels of R248Q, which was critically required for the DNE. Drug-induced targeted protein degradation of R248Q to lower the R248Q:WT ratio restored the transcriptional activity of WT p53, induced antiproliferative effects in cancer cells in vitro, and elicited strong therapeutic activity in vivo. Together, this study provides mechanistic insights into the DNE of p53 missense mutants and indicates that the DNE represents a promising therapeutic target. Significance: Heterotetramerization between R248Q mutant and wild-type p53 in conjunction with supraphysiologic p53R248Q accumulation underlies the dominant-negative effect, highlighting the need to develop pharmacologic strategies to decrease the elevated R248Q:WT ratio. See related commentary by Gencel-Augusto and Lozano, p. 1955.
p53的错义突变体,如常见的热点变体R248Q,在具有单等位基因TP53突变的癌细胞中对野生型(WT)p53发挥显性负效应(DNE)。然而,由于缺乏合适的模型系统,DNE的确切功能和分子机制仍不清楚。在本研究中,我们开发了多种模型系统,包括CRISPR编辑的人同基因细胞系和转录报告细胞系,以及与功能和分子分析相结合的靶向蛋白质降解试验,以从功能上表征DNE。R248Q与WT p53之间形成异源四聚体,通过阻止DNA结合和随后的靶基因反式激活,损害了WT p53的正常功能。此外,R248Q显著增加的蛋白质半衰期导致R248Q的超生理水平,这是DNE所必需的关键因素。药物诱导的R248Q靶向蛋白质降解以降低R248Q:WT比率,恢复了WT p53的转录活性,在体外诱导癌细胞的抗增殖作用,并在体内引发强大的治疗活性。总之,本研究提供了关于p53错义突变体DNE的机制见解,并表明DNE是一个有前景的治疗靶点。意义:R248Q突变体与野生型p53之间的异源四聚化以及超生理的p53R248Q积累是显性负效应的基础,突出了开发降低升高的R248Q:WT比率的药理学策略的必要性。见Gencel-Augusto和Lozano的相关评论,第1955页。